BioSpace News Archive

The Alzheimer’s Association 2024 Alzheimer’s Disease Facts and Figures report reveals that both dementia caregivers and health care workers report difficulties in navigating dementia care within the U.S. health care system.

Tempo Therapeutics, Inc (“Tempo”) a leading innovator in tissue engineering and regenerative medicine, today announced the successful completion of its $12 million Series A equity financing round, led by Galaxy-Sirius Partners and Johnson & Johnson Innovation – JJDC, Inc. (JJDC).

Antengene Corporation Limited (“Antengene” SEHK: 6996.HK) today announced that results of its preclinical studies on ATG-101 (PD-L1/4-1BB bispecific antibody) were published in Cancer Research in a paper titled ATG-101 is a tetravalent PD-L1×4-1BB bispecific antibody that stimulates anti-tumor immunity through PD-L1 blockade and PD-L1-directed 4-1BB activation[1].